The GLP-1 receptor agonist liraglutide showed benefits in young children with obesity, reducing BMI by 5.8% after a year of treatment. Body fat was not directly measured, but improvements in blood pressure and A1c were observed. The FDA approved liraglutide for teens aged 12-17, and a similar agonist for the same age group in 2023. Although some disagreement exists regarding the use of BMI as a surrogate for fat mass, the reduction in BMI was associated with improved metabolic variables. Daily injections may be a challenge for children, but the therapy offers a potential treatment for severe childhood obesity.
Source link
Liraglutide Reduces BMI by Almost 6% in Children Aged 6 to 12
